FR2681786B1 - - Google Patents

Info

Publication number
FR2681786B1
FR2681786B1 FR9111947A FR9111947A FR2681786B1 FR 2681786 B1 FR2681786 B1 FR 2681786B1 FR 9111947 A FR9111947 A FR 9111947A FR 9111947 A FR9111947 A FR 9111947A FR 2681786 B1 FR2681786 B1 FR 2681786B1
Authority
FR
France
Prior art keywords
vectors
diseases
muscle cells
muscle cell
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9111947A
Other languages
English (en)
French (fr)
Other versions
FR2681786A1 (fr
Inventor
Michel Perricaudet
Pascale Briand
Leslie Stratford-Perricaudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9417378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2681786(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9111947A priority Critical patent/FR2681786A1/fr
Priority to CA002097185A priority patent/CA2097185C/fr
Priority to PCT/FR1992/000898 priority patent/WO1993006223A1/fr
Priority to ES92921684T priority patent/ES2147553T5/es
Priority to AT92921684T priority patent/ATE192500T1/de
Priority to AU27902/92A priority patent/AU666142B2/en
Priority to SG1996005855A priority patent/SG49081A1/en
Priority to DE69230993T priority patent/DE69230993T3/de
Priority to DK92921684T priority patent/DK0559884T4/da
Priority to EP92921684A priority patent/EP0559884B2/fr
Priority to JP50585393A priority patent/JP3487597B2/ja
Publication of FR2681786A1 publication Critical patent/FR2681786A1/fr
Publication of FR2681786B1 publication Critical patent/FR2681786B1/fr
Application granted granted Critical
Priority to US09/454,737 priority patent/US6743623B2/en
Priority to GR20000401791T priority patent/GR3034094T3/el
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9111947A 1991-09-27 1991-09-27 Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. Granted FR2681786A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9111947A FR2681786A1 (fr) 1991-09-27 1991-09-27 Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
SG1996005855A SG49081A1 (en) 1991-09-27 1992-09-25 Viral recombinant vectors for expression in muscle cells
DK92921684T DK0559884T4 (da) 1991-09-27 1992-09-25 Rekombinante virusvektorer til ekspression i muskelceller
ES92921684T ES2147553T5 (es) 1991-09-27 1992-09-25 Vectores virales recombinantes para la expresion en unas celulas musculares.
AT92921684T ATE192500T1 (de) 1991-09-27 1992-09-25 Rekombinante viren vektoren zur expression in muskelzellen
AU27902/92A AU666142B2 (en) 1991-09-27 1992-09-25 Viral recombinant vectors for expression in muscle cells
CA002097185A CA2097185C (fr) 1991-09-27 1992-09-25 Vecteurs recombinants viraux pour l'expression dans des cellules musculaires
DE69230993T DE69230993T3 (de) 1991-09-27 1992-09-25 Rekombinante viren vektoren zur expression in muskelzellen
PCT/FR1992/000898 WO1993006223A1 (fr) 1991-09-27 1992-09-25 Vecteurs recombinants viraux pour l'expression dans des cellules musculaires
EP92921684A EP0559884B2 (fr) 1991-09-27 1992-09-25 Vecteurs recombinants viraux pour l'expression dans des cellules musculaires
JP50585393A JP3487597B2 (ja) 1991-09-27 1992-09-25 筋細胞内での発現のためのウイルス性組換え型ベクター
US09/454,737 US6743623B2 (en) 1991-09-27 1999-12-06 Viral recombinant vectors for expression in muscle cells
GR20000401791T GR3034094T3 (en) 1991-09-27 2000-08-02 Viral recombinant vectors for expression in muscle cells.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9111947A FR2681786A1 (fr) 1991-09-27 1991-09-27 Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.

Publications (2)

Publication Number Publication Date
FR2681786A1 FR2681786A1 (fr) 1993-04-02
FR2681786B1 true FR2681786B1 (oth) 1995-05-12

Family

ID=9417378

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9111947A Granted FR2681786A1 (fr) 1991-09-27 1991-09-27 Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.

Country Status (12)

Country Link
EP (1) EP0559884B2 (oth)
JP (1) JP3487597B2 (oth)
AT (1) ATE192500T1 (oth)
AU (1) AU666142B2 (oth)
CA (1) CA2097185C (oth)
DE (1) DE69230993T3 (oth)
DK (1) DK0559884T4 (oth)
ES (1) ES2147553T5 (oth)
FR (1) FR2681786A1 (oth)
GR (1) GR3034094T3 (oth)
SG (1) SG49081A1 (oth)
WO (1) WO1993006223A1 (oth)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538722A (en) * 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
WO1994010322A1 (en) * 1992-10-29 1994-05-11 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
EP0957172B1 (en) 1992-11-18 2005-10-19 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US20020136708A1 (en) 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US6140087A (en) * 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US6080569A (en) 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
CA2166118C (en) * 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
US6120764A (en) * 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
FR2718749B1 (fr) * 1994-04-18 1996-05-31 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
NZ269156A (en) * 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2712812B1 (fr) * 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
CA2188575A1 (en) * 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6974694B2 (en) 1995-06-07 2005-12-13 Advec, Inc. Adenoviruses for control of gene expression
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
CN1261807A (zh) 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 向横纹肌中转移核酸的改进方法和用于实施该方法的组合
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
ATE446368T1 (de) 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
NZ505955A (en) 1998-02-06 2005-04-29 Collateral Therapeutics Inc Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF-A, and pharmaceutical use
EP2261345A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1961813B1 (en) 1998-12-16 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
US6673601B1 (en) 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
EP1721982B1 (en) 1999-04-15 2013-04-10 Boehringer Ingelheim Vetmedica GmbH Chimeric lyssavirus nucleic acids and polypeptides
RU2245366C2 (ru) 1999-04-30 2005-01-27 Чирон С.Р.Л. Антиген neisseria, кодирующая его нуклеиновая кислота, их использование
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT2275552E (pt) 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
EP1261723B1 (en) 2000-02-28 2008-02-27 Novartis Vaccines and Diagnostics S.r.l. Hybrid expression of neisserial proteins
US7238672B1 (en) 2000-04-17 2007-07-03 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
KR20030042003A (ko) * 2000-10-06 2003-05-27 가부시키가이샤 디나벡크 겐큐쇼 골격근에 외래유전자를 도입하기 위한 파라믹소바이러스 벡터
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
FR2829136B1 (fr) 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
PT1497438E (pt) 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005093064A1 (ja) 2004-03-29 2005-10-06 Galpharma Co., Ltd. 新規ガレクチン９改変体タンパク質及びその用途
EP1799243B1 (en) 2004-10-06 2015-07-15 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US8999944B2 (en) 2005-01-20 2015-04-07 University Of Rochester Thioredoxin interacting protein (TXNIP) as regulator of vascular function
US8026354B2 (en) 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008116116A2 (en) 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
EP2331071A1 (en) 2008-09-05 2011-06-15 Institut National De La Sante Et De La Recherche Medicale Novel multimodular assembly useful for intracellular delivery
WO2010107991A2 (en) 2009-03-18 2010-09-23 Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
CN102596221B (zh) 2009-06-10 2019-06-04 纽约大学 病理tau蛋白的免疫靶向
EP2658567A4 (en) 2010-12-28 2014-09-24 Univ Rochester METHOD FOR MODIFYING INSULIN SIGNAL TRANSMISSION BY BILIVERDINREDUCTASE (BVR) AND BVR-DERIVED PEPTIDES
HUE051021T2 (hu) 2011-09-07 2021-01-28 Sinai School Medicine Ceramidáz és sejtek differenciálódása
WO2014063155A1 (en) 2012-10-21 2014-04-24 University Of Rochester Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
WO2017079442A1 (en) 2015-11-04 2017-05-11 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76751A (en) * 1984-11-01 1991-04-15 American Home Prod Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
CA1339346C (en) * 1986-08-01 1997-08-26 Ian Allister Ramshaw Recombinant chimeric vaccine
EP0465529B1 (en) * 1989-03-21 1998-04-29 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
EP0467987A4 (en) * 1989-05-01 1992-07-08 The University Of Notre Dame Du Lac Methods and materials for expression of human plasminogen in a eukaryotic cell system
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines

Also Published As

Publication number Publication date
DK0559884T4 (da) 2004-08-02
EP0559884A1 (fr) 1993-09-15
ATE192500T1 (de) 2000-05-15
ES2147553T5 (es) 2004-11-16
EP0559884B2 (fr) 2004-04-07
DK0559884T3 (da) 2000-10-02
GR3034094T3 (en) 2000-11-30
DE69230993T3 (de) 2004-12-16
CA2097185A1 (fr) 1993-03-28
AU666142B2 (en) 1996-02-01
WO1993006223A1 (fr) 1993-04-01
SG49081A1 (en) 1998-05-18
DE69230993T2 (de) 2000-11-30
CA2097185C (fr) 2007-07-24
DE69230993D1 (de) 2000-06-08
FR2681786A1 (fr) 1993-04-02
JP3487597B2 (ja) 2004-01-19
EP0559884B1 (fr) 2000-05-03
ES2147553T3 (es) 2000-09-16
AU2790292A (en) 1993-04-27
JPH06502771A (ja) 1994-03-31

Similar Documents

Publication Publication Date Title
FR2681786B1 (oth)
CA2223433A1 (en) Ob protein compositions and methods
EP0090505A3 (en) Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
GB2125047B (en) Yeast hybrid vectors and their use for the production of polypeptides
IT1206311B (it) Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.
ATE54167T1 (de) Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
ATE196507T1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
DE69635899D1 (de) Polypeptid, das die differenzierung unterdrueckt
IL73785A (en) Dna sequences encoding for human erythropoietin,vectors including it,host cells transformed by them,process for producing human erythropoietin and pharmaceutical compositions comprising it
PT83813A (de) Eukaryotische fusionsproteine ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
IL74947A (en) Analogs of human gamma interferon having the partial sequence of human gamma interferon and genetic engineering process for the preparation thereof
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
ZA985090B (en) CNS neuroregenerative compositions and methods of use
FR2556365B1 (fr) Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
DE69730967D1 (en) Human dnase ii
ZA961419B (en) Human DNase I variants.
DE69306273D1 (de) Mitogen für die glatte Muskulatur und dessen kodierende DNS
ATE55411T1 (de) Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
MX9806628A (es) Gen de respuesta de diferenciacion terminal mieloide humana novedoso.
CA2242562A1 (en) Human dnase resistant to actin inhibition
JPS6447393A (en) Novel physiologically active polypeptide

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
ST Notification of lapse